Jian Zhou, MD, PhD

07/23/2021

CIO 2023-13 IMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab vs surveillance in hepatocellular carcinoma patients

Purpose: The risk of HCC recurrence after liver resection or ablation with curative intent is 70-80% within 5 years, indicating an unmet need for effective adjuvant therapies. Atezolizuma...

Jeong Heo , MD, PhD;

David Hsieh , MD;

Masatoshi Kudo , MD, PhD;

Han Chu Lee , MD, PhD;

Qinshu Lian , PhD;

Shinichiro Nakamura , MD, PhD;

Kazushi Numata , MD;

Shukui Qin , MD, PhD;

Jessica Spahn , PhD;

Won Young Tak , MD, PhD;

Thomas Uguen , MD;

Edward Cha , PhD;

Lu Wang , MD, PhD, MS;

Minshan Chen , MD, PhD;

Xiaoyu Wen , MD, PhD;

Ann-Lii Cheng , MD, PhD;

Chun Wu , PharmD;

Pierce Chow , MBBS, FRCS, PhD;

Adam Yopp , MD;

Stephen Hack , MBChB;

Jian Zhou , MD, PhD;

11/01/2023

Durvalumab with or without Bevacizumab as Adjuvant Therapy for Patients with Hepatocellular Carcinoma at Risk of Recurrence After Curative Therapy: EMERALD-2

Purpose: Hepatic resection and ablation are standard of care for patients with hepatocellular carcinoma (HCC), but although potentially curative, the risk of recurrence is high (44%–79% a...

Joong-Won Park ;

Peter R. Galle , MD, PhD;

Riccardo Lencioni , MD;

Jennifer J. Knox ;

Jiaqi Fan , MD;

Ann-Lii Cheng , MD, PhD;

Shethah Morgan ;

Jian Zhou , MD, PhD;

Sean Cleary ;

Norihiro Kokudo ;

10/21/2019